Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1975 5
1976 8
1977 6
1978 6
1979 4
1980 9
1981 9
1982 9
1983 12
1984 21
1985 25
1986 13
1987 43
1988 61
1989 72
1990 86
1991 97
1992 112
1993 119
1994 118
1995 123
1996 154
1997 154
1998 204
1999 232
2000 245
2001 243
2002 255
2003 284
2004 314
2005 321
2006 320
2007 282
2008 335
2009 344
2010 422
2011 419
2012 421
2013 491
2014 609
2015 782
2016 928
2017 1046
2018 1088
2019 1101
2020 1337
2021 1470
2022 1369
2023 1275
2024 531

Text availability

Article attribute

Article type

Publication date

Search Results

15,547 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Misawa S, Denda T, Kodama S, Suzuki T, Naito Y, Kogawa T, Takada M, Suichi T, Shiosakai K, Kuwabara S; MiroCIP study group. Misawa S, et al. BMC Cancer. 2023 Nov 11;23(1):1098. doi: 10.1186/s12885-023-11560-4. BMC Cancer. 2023. PMID: 37951905 Free PMC article. Clinical Trial.

From baseline to week 12 (last observation carried forward [LOCF]), NRS score decreased by 30.9%: mean change (95% confidence interval [CI]), - 1.7 (- 2.4 to - 1.0) (p < 0.001). Patients with baseline NRS of 6 experienced a 44.0% reduction in score from baseline to week

…
From baseline to week 12 (last observation carried forward [LOCF]), NRS score decreased by 30.9%: mean change (95% confidence interval [CI]) …
Prevalence of lumbar spondylolysis and spondylolisthesis in patients with degenerative spinal disease.
Aoki Y, Takahashi H, Nakajima A, Kubota G, Watanabe A, Nakajima T, Eguchi Y, Orita S, Fukuchi H, Yanagawa N, Nakagawa K, Ohtori S. Aoki Y, et al. Sci Rep. 2020 Apr 21;10(1):6739. doi: 10.1038/s41598-020-63784-0. Sci Rep. 2020. PMID: 32317683 Free PMC article.

Of these 37 patients, 19 patients (51.4%) showed spondylolisthesis, whereas only 7.4% of non-spondylolysis patients showed spondylolisthesis (p < 0.05). When excluding unilateral spondylolysis, 90% (18/20) of spondylolysis patients aged 60 years-old showed spondylolisth

…
Of these 37 patients, 19 patients (51.4%) showed spondylolisthesis, whereas only 7.4% of non-spondylolysis patients showed spondylolisthesis …
Catalytic asymmetric synthesis of alpha-methyl-p-boronophenylalanine.
Harada S, Kajihara R, Muramoto R, Jutabha P, Anzai N, Nemoto T. Harada S, et al. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1915-1918. doi: 10.1016/j.bmcl.2018.03.075. Epub 2018 Mar 28. Bioorg Med Chem Lett. 2018. PMID: 29655983
p-Boronophenylalanine (l-BPA) is applied in clinical settings as a boron carrier for boron neutron capture therapy (BNCT) to cure malignant melanomas. ...
p-Boronophenylalanine (l-BPA) is applied in clinical settings as a boron carrier for boron neutron capture therapy (BNCT) to cure mal …
Identification of genotype-biochemical phenotype correlations associated with fructose 1,6-bisphosphatase deficiency.
Sakuma I, Nagano H, Hashimoto N, Fujimoto M, Nakayama A, Fuchigami T, Taki Y, Matsuda T, Akamine H, Kono S, Kono T, Yokoyama M, Nishimura M, Yokote K, Ogasawara T, Fujii Y, Ogawa S, Lee E, Miki T, Tanaka T. Sakuma I, et al. Commun Biol. 2023 Jul 28;6(1):787. doi: 10.1038/s42003-023-05160-y. Commun Biol. 2023. PMID: 37507476 Free PMC article.
Here we identify compound heterozygous missense mutations of FBP1, c.491G>A (p.G164D) and c.581T>C (p.F194S), in an adult patient with hypoglycemic lactic acidosis. ...
Here we identify compound heterozygous missense mutations of FBP1, c.491G>A (p.G164D) and c.581T>C (p.F194S), in an adul …
Erratum: figure correction.
Li SX, Zhang JC, Wu J, Hashimoto K. Li SX, et al. Clin Psychopharmacol Neurosci. 2014 Dec;12(3):243. doi: 10.9758/cpn.2014.12.3.243. Clin Psychopharmacol Neurosci. 2014. PMID: 25599759 Free PMC article.
[This corrects the article on p. 124 in vol. 12, PMID: 25191502.]....
[This corrects the article on p. 124 in vol. 12, PMID: 25191502.]....
Cryo-EM structure of P-glycoprotein bound to triple elacridar inhibitor molecules.
Hamaguchi-Suzuki N, Adachi N, Moriya T, Yasuda S, Kawasaki M, Suzuki K, Ogasawara S, Anzai N, Senda T, Murata T. Hamaguchi-Suzuki N, et al. Biochem Biophys Res Commun. 2024 May 21;709:149855. doi: 10.1016/j.bbrc.2024.149855. Epub 2024 Mar 28. Biochem Biophys Res Commun. 2024. PMID: 38579618 Free article.
P-glycoprotein (P-gp) is an ATP-binding cassette transporter known for its roles in expelling xenobiotic compounds from cells and contributing to cellular drug resistance through multidrug efflux. This mechanism is particularly problematic in cancer cells, where it …
P-glycoprotein (P-gp) is an ATP-binding cassette transporter known for its roles in expelling xenobiotic compounds from cells …
Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect.
Yamamoto M, Kurino T, Matsuda R, Jones HS, Nakamura Y, Kanamori T, Tsuji AB, Sugyo A, Tsuda R, Matsumoto Y, Sakurai Y, Suzuki H, Sano M, Osada K, Uehara T, Ishii Y, Akita H, Arano Y, Hisaka A, Hatakeyama H. Yamamoto M, et al. J Control Release. 2022 Dec;352:328-337. doi: 10.1016/j.jconrel.2022.10.032. Epub 2022 Oct 26. J Control Release. 2022. PMID: 36280153
After i.p. administration, the amount of anti-PD-L1 antibody transferred into i.p. tumors increased by approximately eight folds compared to that after i.v. administration. ...Owing to the enhanced delivery, the therapeutic efficacy of anti-PD-L1 antibody in the per …
After i.p. administration, the amount of anti-PD-L1 antibody transferred into i.p. tumors increased by approximately eight fol …
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Neurotherapeutics. 2023 Mar;20(2):518-523. doi: 10.1007/s13311-022-01335-3. Epub 2023 Jan 6. Neurotherapeutics. 2023. PMID: 36607596 Free PMC article.
Despite having greater clinical severity before immunotherapy and lower oral prednisolone doses throughout the course, the early IVMP group (n = 55) showed a higher rate of achievement of MM (P = 0.0040, log-rank test; hazard ratio 1.58, 95% confidence interval [CI] 1.13-2 …
Despite having greater clinical severity before immunotherapy and lower oral prednisolone doses throughout the course, the early IVMP group …
Increased glutamate and glutamine levels and their relationship to astrocytes and dopaminergic transmissions in the brains of adults with autism.
Oya M, Matsuoka K, Kubota M, Fujino J, Tei S, Takahata K, Tagai K, Yamamoto Y, Shimada H, Seki C, Itahashi T, Aoki YY, Ohta H, Hashimoto RI, Sugihara G, Obata T, Zhang MR, Suhara T, Nakamura M, Kato N, Takado Y, Takahashi H, Higuchi M. Oya M, et al. Sci Rep. 2023 Jul 19;13(1):11655. doi: 10.1038/s41598-023-38306-3. Sci Rep. 2023. PMID: 37468523 Free PMC article.
The autism group showed elevated glutamate, glutamine, and myo-inositol (mI) levels compared with the TD group (p = 0.045, p = 0.044, p = 0.030, respectively) and a positive correlation between glutamine and mI levels in the ACC (r = 0.54, p = 0.020). …
The autism group showed elevated glutamate, glutamine, and myo-inositol (mI) levels compared with the TD group (p = 0.045, p = …
Association of frequent hypermethylation with high grade histological subtype in lung adenocarcinoma.
Ito Y, Usui G, Seki M, Fukuyo M, Matsusaka K, Hoshii T, Sata Y, Morimoto J, Hata A, Nakajima T, Rahmutulla B, Kaiho T, Inage T, Tanaka K, Sakairi Y, Suzuki H, Yoshino I, Kaneda A. Ito Y, et al. Cancer Sci. 2023 Jul;114(7):3003-3013. doi: 10.1111/cas.15817. Epub 2023 Apr 21. Cancer Sci. 2023. PMID: 37082886 Free PMC article.

Micropapillary pattern (MPP)-predominant cases and those with MPP components were significantly enriched in HME (p = 0.02 and p = 0.03, respectively). HME cases showed a significantly poor prognosis for recurrence-free survival (p < 0.001) and overall surv

…
Micropapillary pattern (MPP)-predominant cases and those with MPP components were significantly enriched in HME (p = 0.02 and p …
15,547 results
You have reached the last available page of results. Please see the User Guide for more information.